on NANOBIOTIX (EPA:NANO)
Nanobiotix: Financial results and clinical progress in the first half of 2025
French biotechnology company Nanobiotix has released its financial results for the first half of 2025. Operating revenue reached €26.6 million, up from €9.3 million in 2024. This increase is mainly due to an amendment to the contract with Johnson & Johnson.
R&D expenses were €14.5 million, down from €22 million in the previous year, reflecting the transfer of certain expenses to J&J. General expenses remained stable at €11.3 million. Net loss narrowed to €5.4 million, compared to €21.9 million in 2024.
Cash balances reached €28.8 million, sufficient to fund operations through mid-2026. The company is exploring financing options to extend this horizon. Meanwhile, Nanobiotix continues the clinical development of its lead product, JNJ-1900 (NBTXR3).
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NANOBIOTIX news